What Regeneron Ventures does

Regeneron Ventures is a healthcare-focused corporate venture capital fund launched in April 2024 with a $500 million commitment from Regeneron Pharmaceuticals, Inc., which serves as the fund's single and exclusive limited partner. Headquartered in Greenwich, Connecticut, the fund operates independently from its parent LP while sharing Regeneron's patient-centric, science-based mission and values. Its investment mandate spans healthcare broadly but is explicitly skewed toward biotechnology, devices, tools, and enabling technologies, with decisions driven by the quality of people, science, and data, and a stated appetite for breakthrough innovation.

The fund's portfolio as of mid-2026 comprises nine disclosed investments across diverse therapeutic modalities and geographies. Lead or co-lead positions were taken in Tasca Therapeutics ($52M Series A, Dec 2024), Actio Biosciences ($66M Series B co-led with Deerfield, Jun 2025), and Think Bioscience ($55M Series A co-led with Innovation Endeavors, Jan 2026), with participant roles in Atavistik Bio (Dec 2025 and a March 2026 extension totaling $160M), TRIANA Biomedicines ($120M Series B, Dec 2025), Neomorph ($100M Series B, Apr 2026), Coultreon Biopharma ($125M Series A, Apr 2026 — the fund's first European investment), and City Therapeutics ($99.5M Series B, Jun 2026).

As a venture investment vehicle rather than an operating business, Regeneron Ventures does not sell products or services to external customers. Returns are generated through portfolio company exits, IPOs, and distributions to its sole limited partner, Regeneron Pharmaceuticals. Portfolio companies receive not only capital but also strategic support and access to Regeneron's scientific network, expertise, and resources, positioning the fund as a value-add partner rather than a passive allocator.

Name

Regeneron Ventures

Legal name

Regeneron Ventures

Website

https://regeneronventures.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

Regeneron Ventures is a healthcare venture capital fund launched in April 2024 with a $500 million commitment from Regeneron Pharmaceuticals as its sole LP, investing in early-to-mid-stage biotechnology, devices, tools, and enabling technology companies.

Ownership category

akta.pro rank

Product category

Healthcare Venture Capital

NAICS

Other Financial Vehicles (52599)

akta.pro primary industry

Real Estate / PropTech Growth Equity (FSANACAH)

akta.pro secondary industry

GRC, Policy Management & Controls Testing (SOX/ICFR, audit management) (FSAGAFAM)

Keywords

• Healthcare venture capital
• Biotechnology investment
• Early-stage biotech funding
• Therapeutic platform investing
• Enabling technology ventures

Headquarters

HQ city

Greenwich

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations

Core offering

Regeneron Ventures is a healthcare venture capital fund that deploys capital into early- and growth-stage biotechnology, devices, tools, and enabling technology companies. It provides equity financing and strategic support to portfolio companies, with investment decisions grounded in the quality of people, science, and data.

Product overview

Regeneron Ventures is a healthcare venture capital fund launched in April 2024 with a $500 million commitment from Regeneron Pharmaceuticals, Inc. The firm invests in biotechnology, medical devices, tools, and enabling technologies across the healthcare sector. As a venture capital investment vehicle, Regeneron Ventures does not offer commercial products or services in the traditional sense; instead, it provides capital investment and strategic support to early-stage and growth-stage healthcare companies.

Differentiator

Problem solved

Functional benefit

Products and services

• Regeneron Ventures Fund

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves7 records

Expansion highlights4 records

Direct peers

• Pfizer Ventures: Corporate venture arm of Pfizer investing in early-stage biotech and therapeutic platform companies; same CVC model, same healthcare/biotech mandate, and similar LP-of-one structure tied to a major pharma parent.
• Novartis Venture Fund: Corporate venture arm of Novartis focused on early-stage life sciences and biotech investments. Highly comparable CVC structure backing therapeutic platform companies with strategic pharma expertise.
• Leaps by Bayer: Bayer's corporate venture fund investing in breakthrough biotech, healthcare, and agricultural technologies. Same CVC model with strategic pharma parent and similar biotech investment thesis.
• Roche Venture Fund: Corporate venture arm of Roche investing in early- and growth-stage biotech and diagnostics. Direct comparable as a strategic pharma CVC with biotech specialization.
• Sanofi Ventures: Corporate venture capital arm of Sanofi focused on biotech and digital health investments. Direct comparable CVC structure backing early-stage therapeutic companies.
• Amgen Ventures: Corporate venture arm of Amgen investing in biotech and life sciences companies. Comparable CVC structure with strategic pharma backing and similar biotech investment focus.
• ARCH Venture Partners: Leading venture capital firm focused on early-stage biotechnology and life sciences companies. Comparable as a pure-play biotech VC investing in similar therapeutic modalities (molecular glues, allosterics, novel targets).
• Atlas Venture: Early-stage biotech venture capital firm building companies around novel therapeutic platforms. Comparable investment thesis around breakthrough science and platform companies.
• OrbiMed: Healthcare-focused investment firm spanning venture capital, growth equity, and private debt across biopharma, medical devices, and diagnostics. Comparable healthcare-only mandate with similar biotech portfolio exposure.

Broad incumbents

• AbbVie Ventures: Strategic investment arm of AbbVie focused on biotech and pharmaceutical innovation. Comparable CVC structure, though AbbVie's broader commercial pharma presence makes it a larger incumbent in the same therapeutic investment space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments18 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Regeneron Ventures